2010 (English)In: Heart Failure in Clinical Practice / [ed] Michael Y. Henein, Springer London, 2010, 309-318 p.Chapter in book (Other academic)
Natriuretic peptides are clinically used as biomarkers of heart failure and have in recent years become more and more valuable in the diagnosis of heart failure. B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-pro-BNP) have become commercially available, their accurate assays have been made, and their most widespread use has been achieved, although other natriuretic peptides can be of interest as well. The body of data supporting the use of BNP and NT-pro-BNP is steadily increasing. Low levels of BNP and NT-pro-BNP can, because of their high negative predictive values, be used to rule out heart failure, and high levels of these peptides predict a poor prognosis. There are, however, several pitfalls in the use of natriuretic peptides that one has to be aware of when using them in routine clinical practice. Many unanswered questions also remain to be resolved
Place, publisher, year, edition, pages
Springer London, 2010. 309-318 p.
Cardiac and Cardiovascular Systems
IdentifiersURN: urn:nbn:se:umu:diva-75746DOI: 10.1007/978-1-84996-153-0_17ISI: 000284026100017ISBN: 978-1-84996-152-3ISBN: 978-1-84996-153-0OAI: oai:DiVA.org:umu-75746DiVA: diva2:635444